Gene therapy (AAV vector) · Gene replacement · developed by MeiraGTx UK II
AAV-CNGA3 is an adeno-associated virus vector gene therapy that delivers the CNGA3 gene, intended to address defects in that gene. It is being studied in achromatopsia, an inherited color vision disorder.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03758404 | Phase 1/2 | Achromatopsia | Completed | MGTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Achromatopsia
Updated Oct 25, 2026. Something wrong or missing? Report it on the MGTX page.
See MGTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MGTX catalysts and pipeline →